Michael Leek

Company: TC Biopharm

Job title: Co-Founder & Executive Chairman

Seminars:

Panel Discussion: Sharing Perspectives on the Application & Attractiveness of Gamma Delta T Therapy in a Competitive Treatment Landscape 11:30 am

Discussing the pros and cons of gamma delta T therapies as a treatment option for patients vs. standard therapy and analogous immune cell therapies Communicating the key differentiators in the clinic that make gamma delta cells an attractive treatment option Outlining roadblocks to the uptake of gamma delta therapies in the clinic for developers to…Read more

day: Day 2 am track b

Gamma Delta T Therapies – From ‘Last Chance’ to Surrogate Front Line Treatment (Vd2) 3:30 pm

Sharing updates on the use of unmodified allogeneic gamma delta T in phase 1/2a for late stage relapsed and refractory AML Discussing allogeneic cell dosing strategy and examining biomarkers of response Outlining next steps in phase 2/3 follow-up clinical trials, and lessons learnedRead more

day: Day One